Acquisition by Rosenblum Mark J of 6432 shares of Salarius Pharmaceuticals subject to Rule 16b-3

SLRX Stock  USD 1.41  0.07  4.73%   
Slightly above 55% of Salarius Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Salarius Pharmaceuticals suggests that some traders are interested. Salarius Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Salarius Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Salarius Pharmaceuticals Officer Exec Vp Finance, Cfo. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Salarius insider trading alert for acquisition of common stock by Rosenblum Mark J, Officer: Exec Vp Finance, Cfo, on 28th of October 2024. This event was filed by Salarius Pharmaceuticals with SEC on 2023-02-13. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Salarius Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Salarius Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Salarius Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Salarius Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Salarius Pharmaceuticals Fundamental Analysis

We analyze Salarius Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Salarius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Salarius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Salarius Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Salarius Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Salarius Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Salarius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Salarius Pharmaceuticals Related Equities

VCNXVaccinex   11.14   
0%
100.0%
SABSSAB Biotherapeutics   4.27   
0%
38.0%
ARTLArtelo Biosciences   0.93   
0%
8.0%
CRVSCorvus Pharmaceuticals   0.36   
0%
3.0%
PIRSPieris Pharmaceuticals   2.01   
18.0%
0%
MREOMereo BioPharma   2.20   
19.0%
0%
AKTXAkari Therapeutics   5.15   
46.0%
0%
GOVXGeoVax Labs   7.11   
63.0%
0%
ALRNAileron Therapeutics   8.77   
78.0%
0%
NTRBNutriband   9.01   
80.0%
0%
AFMDAffimed NV   10.43   
93.0%
0%

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.